Imovax D.T. Adult (Diphtheria Toxoid, Tetanus Toxoid, Algeldrate)

The vaccine contains chemically inactivated forms of the diphtheria and tetanus toxins (toxoids). When injected, antigen‑presenting cells process the toxoids and present them to T cells, which activate B cells to produce high‑affinity neutralising antibodies. These antibodies bind to the native toxins if encountered, neutralising their harmful effects and providing active immunity.

The dose and schedule of Imovax D.T. Adult are determined by the prescribing healthcare professional based on national immunisation guidelines, the patient’s age, previous vaccination history, and clinical circumstances. The product is supplied as a single‑dose injectable solution, and the prescriber decides the exact volume and timing of administration.

Safety data for Imovax D.T. Adult in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should evaluate the potential benefits of protecting the mother against diphtheria and tetanus against any theoretical risks before administering the vaccine to pregnant or nursing women.

To place an order, submit an enquiry on the Imovax D.T. Adult product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, cold‑chain shipping details and any necessary import documentation.

Imovax D.T. Adult is an EU‑approved toxoid vaccine that uses algeldrate as an adjuvant to enhance immune response. Compared with some alternatives that may contain aluminium salts, algeldrate can provide comparable immunogenicity with a slightly different reactogenicity profile. Clinical efficacy in preventing diphtheria and tetanus is similar across licensed toxoid vaccines when administered according to recommended schedules.

Imovax D.T. Adult must be stored at 2 °C to 8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Maintaining the cold chain throughout distribution and handling is essential to preserve vaccine potency.

The vaccine is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. A qualified healthcare professional selects the appropriate injection site—commonly the deltoid muscle for intramuscular administration—and follows aseptic technique. The volume administered is defined by the prescribing information and the prescriber’s instructions.

Serious adverse events, although rare, include anaphylactic reactions that require immediate medical intervention, Guillain‑Barré syndrome presenting as progressive muscle weakness, and severe neurologic or febrile reactions such as seizures. Patients should be observed for a short period after vaccination, and any signs of severe allergic response or neurological symptoms should prompt urgent evaluation.

Individuals with a documented severe allergy to any component of the vaccine—including diphtheria or tetanus toxoid or the adjuvant algeldrate—should not receive Imovax D.T. Adult. Additionally, persons who experienced a severe allergic reaction (e.g., anaphylaxis) after a previous dose of this vaccine should avoid further administration.